- Cantor Fitzgerald raised the price target on Abeona Therapeutics Inc (NASDAQ:ABEO) from $22 to $40 after adjusting the market model/ increasing the probability of success for EB-101.
- Last week, the company reported topline data from the pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB).
- The study met its two co-primary efficacy endpoints demonstrating statistically significant, clinically meaningful improvements in wound healing and pain reduction in large chronic RDEB wounds.
- The analyst increased the probability of success from 70% to 85% to reflect the positive data and believes the data supporting EB-101 to become the standard of care for RDEB.
- Cantor emphasizes its belief Abeona is the only company to now show positive pivotal data in RDEB when evaluating the larger, chronic wounds.
- The positive data and capital raise of $35 million remove a financial overhang on the company, and investors can focus on the next step of potential commercialization, the analyst writes.
- Price Action: ABEO shares are down 0.41% at $3.655 on the last check Tuesday.
- Photo Via Company
‘Elon Musk Would Probably Disagree,’ But Expert Says ‘Investors Don’t See Tesla As An AI Play Like Most Of The Other Magnificent Seven Stocks’
As Tesla struggles with plummeting stock prices, investors are questioning its place among the "Magnificent Seven" tech stocks that have been driving the S&P 500 Index to new heights.
